Excerpted and adapted from:
Fleischmann RM, Wagner F, Kivitz AJ, et al. Safety, tolerability, and pharmacodynamics of ABT-122, a tumor necrosis factor and interleukin 17–targeted dual variable domain immunoglobulin, in patients with rheumatoid arthritis. Arthritis Rheumatol. 2017 Dec;69(12):2283–2291.
You are here: / / Safety, Tolerability & Pharmacodynamics of ABT-122 in Patients with RA